You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

    SBC: NUVOX PHARMA, L.L.C.            Topic: 102

    Glioblastoma multiforme (GBM) is a malignant primary brain tumor affecting about 12,000 new cases per year in the U.S. Average survival is only about 14-15 months. Radiation (RT) is most commonly administered as 30 fractions of 2 Gray each over 6-weeks with concomitant temozolomide (TMZ). GBM tumors are hypoxic. The primary mechanism of RT is creation of singlet oxygen; hypoxia within GBM adversel ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  2. An Integrated Microarray Printing and Detection System

    SBC: BIOSENSING INSTRUMENT INC            Topic: 400

    DESCRIPTIONprovided by applicantMicroarray technology has dramatically advanced the study of protein interactions leading to discovery and validation of new biomarkers and therapeutic drugsTypicallyprotein microarrays are pre spotted with target molecules in one device and then tested with probe molecules using another deviceDuring each testing cyclethe entire microarray becomes exposed to the pro ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  3. A Phase 2 clinical trial of topical uracil for the prevention of capecitabine induced hand-foot syndrome

    SBC: NANOMETICS LLC            Topic: 102

    Problem to be SolvedCapecitabine is a widely prescribed and orally available prodrug of the chemotherapeutic agentfluorouracilFUThe principle dose schedule limiting toxicity associated with its use is Hand Foot syndromeHFSand occurs inof patients receiving capecitabineHFS manifests in the hands and feet of patientsand rapidly progresses to painful peelingblisteringand bleeding that commonly requir ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  4. OpenBeds: Improving the Delivery of Care for Patients with Drug Addiction

    SBC: Openbeds Inc.            Topic: NIDA

    There is an urgent need for more effective mechanisms that leverage current technologies and best practices to both identify capacity and refer patients to drug treatment facilitiesThe applicant organizationOpenBeds Incis partnering with the non profit MESH Coalitionthree of the largest health care systems offering drug treatment in Indiana and the Indiana Division of Mental Health and AddictionDM ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Automation of a Liver Genotoxicity Assay

    SBC: Litron Laboratories Ltd            Topic: NIEHS

    DESCRIPTIONprovided by applicantAssessment of chemicalspotential to cause chromosomal damage is an established and important part of preclinical genotoxicity safety testing for many consumer productsindustrial chemicalsand all pharmaceutical agentsCurrently the mammalian erythrocyte micronucleus test is the most commonly employed assay for in vivo assessment of chromosomal damagebut this assay rep ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Tools for Accelerating R&D for Historically Understudied Protein Kinases

    SBC: LUCEOME BIOTECHNOLOGIES, L.L.C.            Topic: NCATS

    Protein kinases are central players in almost every aspect of human physiology and serve as critical mediators of signal transductionThe dysfunction of many kinases is implicated in cancerdiabetesinflammationand cardiovascular diseases and many are validated targets for therapeutic interventionThe human genome encodesprotein kinasesYettheor so marketed protein kinase drugstarget only a small fract ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil

    SBC: ADJUVANCE TECHNOLOGIES INC.            Topic: NIAID

    PROJECT SUMMARY Vaccines against infectious diseases continue to improve public health across the worldWith increased knowledge of etiologic pathogens and necessary immune responses have come increasingly safe and defined or targeted vaccinesThe success of defined vaccines requires use of an immunological adjuvant to permit more effective immunizationFew adjuvants have sufficient potency and accep ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Optimization of Supercritical Carbon Dioxide Based Virus Inactivation, Characterized by Protein Damage and Maintenance of Epitope Integrity in Vaccine Sterilization

    SBC: NOVASTERILIS, INC.            Topic: R

    Project Summary The process combining supercritical COand co sterilants produces strong synergistic microbicidal effects in relatively mild conditionsThe mechanism of microbe inactivation is not well characterizedbut the disruption of lipid membranes and mild oxidative damage appear to be involvedThe processwhich is also highly efficient against virusesis considered to be very mild compared to oth ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Ecosystem for credentialing and supporting a bilingual provider workforce

    SBC: Transcendent International, LLC            Topic: 102

    Limited English proficientLEPpatients who struggle to understand their care providers report difficulty navigating both administrative and clinical proceduresleading to poorer outcomes than their English proficient counterpartsDespite numerous federal and state mandates requiring adequate language assistancehealthcare organizations have had limited success in implementing appropriate servicesFacin ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Next generation CRISPR/Cas9-RNAi mouse models for accelerated drug discovery research

    SBC: MIRIMUS INC            Topic: 100

    Abstract SignificanceNew approaches for rapid identification and early preclinical validation of novel therapeutic targets are crucial to make importantgo no godecisions and curb the cost of developing new cancer treatmentsGenetically engineered mouse modelsGEMMsare a powerful platform to study disease initiation and maintenancethe tumor microenvironment and the responsiveness of cancers to known ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government